Skip to Main Content
Sign in to myUHN Patient Portal

Clinical Trials Search Results

 

 

449412709564/20/2018 12:04:16 PMThe breast MRI is used in the preoperative scenario to evaluate the extension of a newly diagnosed breast cancer and to screen the contralateral breast STS_ListItem_GenericListhttp://www.uhn.ca/PrincessMargaret/Research/Cancer_Clinical_Research/Lists/PMCP Clinical Trials Data/AllItems.aspx0http://www.uhn.ca4/20/2018 12:04:16 PMFalse3131~sitecollection/_catalogs/masterpage/UHN/templates/PMCP_Item_Clinical_Trials.js
449414709854/20/2018 12:03:47 PMincluding a synchronous contralateral breast cancer (Note Patients found to have a contralateral breast cancer on study imaging following STS_ListItem_GenericListhttp://www.uhn.ca/PrincessMargaret/Research/Cancer_Clinical_Research/Lists/PMCP Clinical Trials Data/AllItems.aspx0http://www.uhn.ca4/20/2018 12:03:47 PMFalse3131~sitecollection/_catalogs/masterpage/UHN/templates/PMCP_Item_Clinical_Trials.js
44936072444/20/2018 11:58:27 AMwidespread acceptance for use in breast reconstruction and other areas and has the potential to provide support to the breast implant without tissue expansion in a STS_ListItem_GenericListhttp://www.uhn.ca/PrincessMargaret/Research/Cancer_Clinical_Research/Lists/PMCP Clinical Trials Data/AllItems.aspx0http://www.uhn.ca4/20/2018 11:58:27 AMFalse3131~sitecollection/_catalogs/masterpage/UHN/templates/PMCP_Item_Clinical_Trials.js
449480710314/20/2018 12:03:46 PMwho are overweight or obese when their breast cancer is found (diagnosed) have a greater risk of their breast cancer recurring, as compared to women who were STS_ListItem_GenericListhttp://www.uhn.ca/PrincessMargaret/Research/Cancer_Clinical_Research/Lists/PMCP Clinical Trials Data/AllItems.aspx0http://www.uhn.ca4/20/2018 12:03:46 PMFalse3131~sitecollection/_catalogs/masterpage/UHN/templates/PMCP_Item_Clinical_Trials.js
44935572864/20/2018 11:59:12 AMALA-induced Fluorescence Imaging of Breast Cancers Using the Handheld PRODIGI Imaging but is not specific enough to detect a difference across all breast tumor types STS_ListItem_GenericListhttp://www.uhn.ca/PrincessMargaret/Research/Cancer_Clinical_Research/Lists/PMCP Clinical Trials Data/AllItems.aspx0http://www.uhn.ca4/20/2018 11:59:12 AMFalse3131~sitecollection/_catalogs/masterpage/UHN/templates/PMCP_Item_Clinical_Trials.js
44930072954/20/2018 11:59:25 AM2. Clinical stage T1-3 N1 M0 breast cancer at diagnosis (prior to the start of Benign breast disease, LCIS or DCIS of contralateral breast is allowed STS_ListItem_GenericListhttp://www.uhn.ca/PrincessMargaret/Research/Cancer_Clinical_Research/Lists/PMCP Clinical Trials Data/AllItems.aspx0http://www.uhn.ca4/20/2018 11:59:25 AMFalse3131~sitecollection/_catalogs/masterpage/UHN/templates/PMCP_Item_Clinical_Trials.js
44930277014/20/2018 12:02:00 PMAge ≥18 years (or per national multifocal and/or bilateral early invasive breast cancer are eligible if all Patients with Stage I or IV breast cancer are not eligible STS_ListItem_GenericListhttp://www.uhn.ca/PrincessMargaret/Research/Cancer_Clinical_Research/Lists/PMCP Clinical Trials Data/AllItems.aspx0http://www.uhn.ca4/20/2018 12:02:00 PMFalse3131~sitecollection/_catalogs/masterpage/UHN/templates/PMCP_Item_Clinical_Trials.js
449220709954/20/2018 12:05:22 PMWith Locally Advanced or Metastatic PIK3CA-Mutant Hormone-Receptor Positive Breast Cancer in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer STS_ListItem_GenericListhttp://www.uhn.ca/PrincessMargaret/Research/Cancer_Clinical_Research/Lists/PMCP Clinical Trials Data/AllItems.aspx0http://www.uhn.ca4/20/2018 12:05:22 PMFalse3131~sitecollection/_catalogs/masterpage/UHN/templates/PMCP_Item_Clinical_Trials.js
44940076344/20/2018 12:00:51 PM15-20% of early breast cancers have high levels of a protein called HER2 which is that, in women receiving treatment for breast cancer, heart edema detected by MRI at STS_ListItem_GenericListhttp://www.uhn.ca/PrincessMargaret/Research/Cancer_Clinical_Research/Lists/PMCP Clinical Trials Data/AllItems.aspx0http://www.uhn.ca4/20/2018 12:00:51 PMFalse3131~sitecollection/_catalogs/masterpage/UHN/templates/PMCP_Item_Clinical_Trials.js
449231710204/20/2018 12:05:07 PMActivity of GSK525762 in Combination With Fulvestrant in Subjects With ER+ Breast Cancer in women with advanced or metastatic ER+ breast cancer, who have disease that has STS_ListItem_GenericListhttp://www.uhn.ca/PrincessMargaret/Research/Cancer_Clinical_Research/Lists/PMCP Clinical Trials Data/AllItems.aspx0http://www.uhn.ca4/20/2018 12:05:07 PMFalse3131~sitecollection/_catalogs/masterpage/UHN/templates/PMCP_Item_Clinical_Trials.js

~sitecollection/_catalogs/masterpage/Display Templates/Search/Item_Default.js
~sitecollection/_catalogs/masterpage/Display Templates/Search/Item_Default.js
~sitecollection/_catalogs/masterpage/Display Templates/Search/Item_Default.js
~sitecollection/_catalogs/masterpage/Display Templates/Search/Item_Default.js
~sitecollection/_catalogs/masterpage/Display Templates/Search/Item_Default.js
~sitecollection/_catalogs/masterpage/Display Templates/Search/Item_Default.js
~sitecollection/_catalogs/masterpage/Display Templates/Search/Item_Default.js
~sitecollection/_catalogs/masterpage/Display Templates/Search/Item_Default.js
~sitecollection/_catalogs/masterpage/Display Templates/Search/Item_Default.js
~sitecollection/_catalogs/masterpage/Display Templates/Search/Item_Default.js
~sitecollection/_catalogs/masterpage/Display Templates/Search/Item_Default.js
~sitecollection/_catalogs/masterpage/Display Templates/Search/Item_Default.js

Last reviewed:
Last modified: 6/16/2017 6:07 AM